Clinical profiles of patients referred for biological therapy and major limitations in the qualification paths in a specialist asthma centre
Authors:
- 1 January 2023
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 40 (1) , 93-101
Abstract
Introduction: Despite the proven efficacy of biologics in the treatment of severe asthma, still a limited number of patients are included in the Polish therapeutic programme. Aim: To identify major limitations in the qualification paths and predominant reasons leading to exclusion from available biologic treatments. The clinical profiles of patients referred for biologics were also examined. Material and methods: Data on demographic characteristics, clinical profile, biomarkers, and medical history from one visit of patients that had been referred for qualification for biologics in 2018/2019 to the Barlicki Hospital (Po- land) were collected. A comparison between eligible and ineligible patients was made. Results: Within 2 years, only 116 patients had been referred to the biologic therapy of whom 93 (80%) had been suitable for the biologic programme. Criteria for the omalizumab programme included major limitations such as: frequent use of oral corticosteroids in the past, and serum total-IgE 30-1000 IU/ml, and for mepolizumab were blood eosinophil count (EOScount) > 350/mu l and spirometric criterion. Ineligible patients had a significantly lower EOScount and better lung function than eligible individuals despite no significant differences in the number of exacerbations or quality of life between groups. A high percentage of ineligible patients had been referred to re-verify the diagnosis of severe asthma. Conclusions: Potential limitations for biologic therapy include restrictive criteria limiting the group of patients to the most severe cases and referring patients with difficult-to-treat asthma without a differential diagnosis. Low awareness and knowledge among physicians who often are not familiar with qualification criteria require extensive education.Keywords
This publication has 25 references indexed in Scilit:
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Importance of concomitant local and systemic eosinophilia in uncontrolled asthmaEuropean Respiratory Journal, 2014
- Eligibility for treatment with omalizumab in Italy and GermanyRespiratory Medicine, 2014
- Adult-onset asthma: is it really different?European Respiratory Review, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- State of the art paper Therapeutic options for severe asthmaArchives of Medical Science, 2012
- Refractory asthma in the UK: cross-sectional findings from a UK multicentre registryThorax, 2010
- Cluster Analysis and Clinical Asthma PhenotypesAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007